Indoleacetic acid
|
Basic information |
| Metabolite name | Indoleacetic acid |
 | HMDB0000197 |
 |
C00954 |
 |
802 |
| Synonyms | Indole acetic acid; |
| No. of studies | 27 |
|
Basic information |
| Metabolite name | Indoleacetic acid |
| HMDB0000197 |
|
C00954 |
|
802 |
| Synonyms | Indole acetic acid; |
| No. of studies | 27 |
|
Relationship between Indoleacetic acid and depression (count: 27) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M008 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M011 | Type4 | placebo-treated responder group vs. non-responder group | Serum | Human | Unknown |
| Study M019 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M022 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M024 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type2 | CUMS + middle dose of Xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M024 | Type2 | CUMS + fluoxetine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M024 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M024 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M068 | Type2 | CUMS + citalopram group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M087 | Type2 | esketamine group 2-h vs. baseline | Plasma | Human | Down |
| Study M087 | Type2 | ketamine group 2-h vs. baseline | Plasma | Human | Down |
| Study M1008 | Type2 | CCFM1025 group vs. placebo group | Faece | Human | Up |
| Study M1010 | Type1 | CUMS group vs. control group | Faece | ICR mouse | Down |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M1063 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Faece | Cynomolgus monkey | Down |
| Study M1090 | Type1 | CUMS group vs. control group | Plasma | BALb/c mouse | Up |
| Study M1105 | Type1 | psychological stress group vs. control group | Faece | C57BL/6 J mouse | Down |
| Study M1135 | Type1 | PSD group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M1142 | Type2 | MDD group, after intermittent theta burst stimulation vs. baseline | Plasma | Human | Up |
| Study M136 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M136 | Type2 | CUMS + moderate dose of ZZHPD group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M136 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M136 | Type2 | CUMS + high dose of ZZHPD group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M531 | Type2 | MDD with escitalopram/citalopram treatment, 8-week vs. baseline | Plasma | Human | Up |
| Study M766 | Type1 | CUS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M777 | Type1 | HFCS-MFD group vs. control group | Serum | C57Bl/6J mouse | Down |
| Study M835 | Type1 | CRS group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M850 | Type1 | reserpine group vs. control group | Brain | C57BL/6 mouse | Down |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Down |
| Study M912 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M985 | Type1 | CUMS group vs. control group | Colon | C57BL/6J mouse | Down |